Pilot study of interferon-α with and without amantadine for the treatment of hepatitis C in HIV co-infected individuals on antiretroviral therapy

Infection

Volumn 29, Issue 5, 2001, Pages 267-270

  Sax, H ^a   Friedl, A ^b   Renner, E ^b   Steuerwald, M H ^c   Weber, R ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Amantadine; Hepatitis C; HIV; Interferon; Treatment

Indexed keywords

ALPHA INTERFERON; AMANTADINE SULFATE; ANTIRETROVIRUS AGENT; HEPATITIS C ANTIBODY; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; AMANTADINE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SELECTION; PROSPECTIVE STUDIES;

EID: 0034816346     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-001-2045-2     Document Type: Article

References (21)

1. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
2. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients
3. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
4. Pathogenesis, diagnosis and management of hepatitis C
5. Pathogenesis, natural history, treatment, and prevention of hepatitis C
6. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
7. Efficacy of combined interferon and ribavirin for treatment of hepatitis C
8. Ribavirin antagonizes the effect of azidothymidine on HIV replication
9. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients
10. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
11. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
12. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count
13. Treatment of chronic hepatitis C with amantadine
14. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients
15. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
16. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C
17. The impact of co-infection With hepatitis C virus and HIV on the tolerability of antiretroviral therapy
18. High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial
19. Aggressive daily interferon therapy in HIV-HCV co-infected patients
20. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy
21. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C